BMS-986322 + famotidine

BMS-986322 + famotidine is an investigational oral combination therapy of the selective tyrosine kinase 2 (TYK2) inhibitor lomedeucitinib (BMS-986322) with famotidine, a histamine H2 receptor antagonist. BMS-986322 was developed for the treatment of moderate-to-severe psoriasis as a second-generation TYK2 inhibitor designed to inhibit cytokine-driven signaling implicated in immune-mediated inflammatory conditions. It was evaluated in phase 2 clinical trials but has been deprioritized in favor of Bristol Myers Squibb’s earlier TYK2 inhibitor, deucravacitinib. Famotidine is included for potential drug-drug interaction or gastric tolerability studies, not as a mechanism-based combination. The fixed combination is not an approved product and represents a research-phase investigational pairing, typically to assess pharmacokinetic or acid suppression effects in healthy participants or psoriasis patients[1][2][5][6][7][8][9].